Market Research Report
Chlamydia Infections - Pipeline Review, H2 2018
|Published by||Global Markets Direct||Product code||200439|
|Published||Content info||72 Pages
Delivery time: 1-2 business days
|Chlamydia Infections - Pipeline Review, H2 2018|
|Published: September 26, 2018||Content info: 72 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chlamydia Infections - Pipeline Review, H2 2018, provides an overview of the Chlamydia Infections (Infectious Disease) pipeline landscape.
Chlamydia is a sexually transmitted infection caused by a bacterium. Symptoms include burning feeling during urination, discharge from the penis or vagina, pain in the lower abdomen, bleeding between periods and pain and swelling around the testicles. Predisposing factors include age, multiple sex partners and history of prior sexually transmitted infection. Treatment includes antibiotics and pain medicine.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chlamydia Infections - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Chlamydia Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chlamydia Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chlamydia Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 1, 10 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 4 and 1 molecules, respectively.
Chlamydia Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.